November 16, 2020 — Among patients who stopped taking their cholesterol-lowering statin medication due to side effects ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
November 16, 2020 — Novartis announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11 ...
November 9, 2020 — A National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of hydro ...
Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...
Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...
The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...
Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...
Gregg Stone, M.D., presents the results of a pooled analysis of randomized trials of bivalirudin virus heparin in acute ...
October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...
October 1, 2020 — Medtronic has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual ...
September 25, 2020 — Short-term hydroxychloroquine treatment is not associated with lethal heart rhythms in patients ...
September 24, 2020 — Analyzing anonymized patient medical records, University of California (UC) San Diego Health resear ...
September 17, 2020 — Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact of C ...
September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials ...